
Milestone Pharmaceuticals Inc. — Investor Relations & Filings
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company's lead investigational product is etripamil, a novel, fast-acting calcium channel blocker delivered as a nasal spray. This formulation is designed for patient self-administration to terminate episodes of certain heart rhythm disturbances outside of a hospital or emergency department setting. The primary indications under investigation for etripamil are paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to address unmet needs for acute, at-home treatment of these episodic conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-05-13 | English | |
| 8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-05-13 | English | |
| 10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-05-13 | English | |
| SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject) | 2026-03-26 | English | |
| 3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer) | 2026-03-23 | English | |
| 8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-03-20 | English |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45772669 | S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-05-13 | English | ||
| 45561982 | 8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-05-13 | English | ||
| 45558367 | 10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-05-13 | English | ||
| 33052631 | SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject) | 2026-03-26 | English | ||
| 33016867 | 3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer) | 2026-03-23 | English | ||
| 32998631 | 8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-03-20 | English | ||
| 32998457 | 10-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer) | 2026-03-20 | English | ||
| 29473554 | 4/A Filing | 2026-02-05 | English | ||
| 29471051 | 4/A Filing | 2026-02-05 | English | ||
| 29470993 | 4/A Filing | 2026-02-05 | English | ||
| 29470829 | 4/A Filing | 2026-02-05 | English | ||
| 29470753 | 4/A Filing | 2026-02-05 | English | ||
| 29473607 | 4 Filing | 2026-02-04 | English | ||
| 29470850 | 4 Filing | 2026-02-04 | English | ||
| 29470788 | 4 Filing | 2026-02-04 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
Milestone Pharmaceuticals Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/9643/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=9643 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=9643 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=9643 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 9643}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Milestone Pharmaceuticals Inc. (id: 9643)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.